Yüksel Ürün argues EV+pembrolizumab outperforms gem/cis in MIBC with large event-free and overall survival benefits, calling it “replacement” rather than incremental improvement.
EVP just ended that era regardless of cispaltin eligibility.
EV + pembrolizumab vs gem/cis in MIBC: Event-free survival HR: 0.40, overall survival was HR: 0.50
This isn't just improvement.
It's replacement...
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare